BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Park J, Lee SR, Choi EK, Kwon S, Jung JH, Han KD, Cha MJ, Ko SB, Oh S, Lip GYH. Effectiveness and Safety of Direct Oral Anticoagulant for Secondary Prevention in Asians with Atrial Fibrillation. J Clin Med 2019;8:E2228. [PMID: 31861095 DOI: 10.3390/jcm8122228] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Chao TF, Joung B, Takahashi Y, Lim TW, Choi EK, Chan YH, Guo Y, Sriratanasathavorn C, Oh S, Okumura K, Lip GYH. 2021 Focused update of the 2017 consensus guidelines of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation. J Arrhythm 2021;37:1389-426. [PMID: 34887945 DOI: 10.1002/joa3.12652] [Reference Citation Analysis]
2 Lee SR, Choi EK, Park SH, Jung JH, Han KD, Oh S, Lip GYH. Off-label underdosed apixaban use in Asian patients with non-valvular atrial fibrillation. Eur Heart J Cardiovasc Pharmacother 2021:pvab004. [PMID: 33471125 DOI: 10.1093/ehjcvp/pvab004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
3 Guo Z, Ding X, Ye Z, Chen W, Chen Y. Non-vitamin K antagonist oral anticoagulants versus vitamin K antagonists in atrial fibrillation patients with previous stroke or intracranial hemorrhage: A systematic review and meta-analysis of observational studies. Clin Cardiol 2021;44:917-24. [PMID: 34013988 DOI: 10.1002/clc.23647] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Kok T, de Boer H, Witteman B, Hovens M, van Luin M, Monajemi H. Anti-Xa Levels in Morbidly Obese Patients Using Apixaban or Rivaroxaban, Before and After Bariatric Surgery. Obes Surg 2021. [PMID: 34822108 DOI: 10.1007/s11695-021-05814-y] [Reference Citation Analysis]
5 Lee SR, Choi EK, Park SH, Jung JH, Han KD, Oh S, Lip GYH. Comparing Warfarin and 4 Direct Oral Anticoagulants for the Risk of Dementia in Patients With Atrial Fibrillation. Stroke 2021;52:3459-68. [PMID: 34496627 DOI: 10.1161/STROKEAHA.120.033338] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Anghel L, Sascău R, Trifan A, Zota IM, Stătescu C. Non-Vitamin K Antagonist Oral Anticoagulants and the Gastrointestinal Bleeding Risk in Real-World Studies. J Clin Med 2020;9:E1398. [PMID: 32397355 DOI: 10.3390/jcm9051398] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
7 Liu PY, Choi EK, Kim TS, Kuo JY, Lee JM, On YK, Park SW, Park HW, Shin DG, Wang L, Yen HW, Lee MH; XaMINA Investigators. XaMINA: A Real-World, Prospective, Observational Study of Treatment-Naïve Patients Treated with Rivaroxaban for Stroke Prevention in Atrial Fibrillation in Asia. Adv Ther 2022. [PMID: 35616848 DOI: 10.1007/s12325-022-02102-8] [Reference Citation Analysis]
8 Diener HC, Hankey GJ, Easton JD, Lip GYH, Hart RG, Caso V. Non-vitamin K oral anticoagulants for secondary stroke prevention in patients with atrial fibrillation. Eur Heart J Suppl 2020;22:I13-21. [PMID: 33093818 DOI: 10.1093/eurheartj/suaa104] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Kirita K, Kodaka Y, Shibata Y, Ueki N, Agawa S, Yamawaki H, Niikura R, Yamamichi N, Izumi K, Hojo M, Maruyama K, Yamamoto T, Gudis K, Watanabe M, Kaise M, Iwakiri K, Futagami S. Impact of clinical characteristics of colonic diverticular bleeding in extremely elderly patients treated with direct oral anti-coagulant drugs: a retrospective multi-center study. J Clin Biochem Nutr 2021;69:222-8. [PMID: 34616113 DOI: 10.3164/jcbn.20-140] [Reference Citation Analysis]
10 Akao M, Shimizu W, Atarashi H, Ikeda T, Inoue H, Okumura K, Koretsune Y, Tsutsui H, Toyoda K, Hirayama A, Yasaka M, Yamashita T, Yamaguchi T, Teramukai S, Kimura T, Kaburagi J, Takita A. Oral Anticoagulant Use in Elderly Japanese Patients With Non-Valvular Atrial Fibrillation - Subanalysis of the ANAFIE Registry. Circ Rep 2020;2:552-9. [PMID: 33693180 DOI: 10.1253/circrep.CR-20-0082] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Choi EK. Cardiovascular Research Using the Korean National Health Information Database. Korean Circ J 2020;50:754-72. [PMID: 32725984 DOI: 10.4070/kcj.2020.0171] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 15.5] [Reference Citation Analysis]
12 Hellerman Itzhaki M, Greenberg N, Margalit I, Shochat T, Krause I, Goldberg E. Risk of stroke and other thromboembolic complications after interruption of DOAC therapy compared with warfarin therapy in patients with atrial fibrillation: a retrospective cohort analysis. J Investig Med 2021:jim-2020-001497. [PMID: 34353884 DOI: 10.1136/jim-2020-001497] [Reference Citation Analysis]
13 Matusik PT, Heleniak Z, Papuga-Szela E, Plens K, Lelakowski J, Undas A. Chronic Kidney Disease and Its Impact on a Prothrombotic State in Patients with Atrial Fibrillation. J Clin Med 2020;9:E2476. [PMID: 32752262 DOI: 10.3390/jcm9082476] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]